Jian Irish - Sep 5, 2025 Form 4 Insider Report for Metagenomi, Inc. (MGX)

Role
Chief Executive Officer, Director
Signature
/s/ Matthew L. Wein, attorney-in-fact
Stock symbol
MGX
Transactions as of
Sep 5, 2025
Transactions value $
$394,700
Form type
4
Date filed
12/1/2025, 07:28 PM
Previous filing
Jun 9, 2025
Next filing
Dec 8, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Irish Jian Chief Executive Officer, Director C/O METAGENOMI, INC., 5959 HORTON STREET, 7TH FLOOR, EMERYVILLE /s/ Matthew L. Wein, attorney-in-fact 2025-12-01 0001995697

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGX Common Stock Sale -$2.9K -1.6K -0.5% $1.81 317K Sep 5, 2025 Direct F1, F2
transaction MGX Common Stock Award $60K +37.5K +11.83% $1.60 354K Dec 1, 2025 Direct F3
transaction MGX Common Stock Award $338K +211K +59.53% $1.60 565K Dec 1, 2025 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGX Stock Option (Right to Buy) Award $0 +225K $0.00 225K Dec 1, 2025 Common Stock 225K $1.60 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units ("RSUs") granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person.
F2 Includes 1,500 shares acquired under the Company's employee stock purchase plan ("ESPP") on May 30, 2025 and 1,500 shares acquired under the Company's ESPP on November 28, 2025.
F3 These shares represent RSUs. 25% of the RSUs shall vest on December 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F4 These shares represent RSUs. 50% of the RSUs shall vest on December 5, 2026, with the remainder vesting on December 5, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F5 25% of the shares subject to this option shall vest and become exercisable on November 6, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.